As clinical signs and symptoms of SARS-CoV-2, influenza or RSV are similar, it is vital to correctly detect them. Credit: Ewa Urban from Pixabay.

The US Food and Drug Administration (FDA) has granted emergency use authorization (EUA) to Qiagen’s NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage Assay, expanding its Covid-19 portfolio.

This polymerase chain reaction (PCR) multiplex test can aid in both qualitative detection and differentiation of influenzas A and B, respiratory syncytial virus (RSV) and SARS-CoV-2 infections within 80 minutes.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

With Covid-19 restrictions being eased and social distancing measures reduced, the chances of respiratory viral infections are expected to increase, QIAGEN noted.

As clinical signs and symptoms of respiratory viral infection due to SARS-CoV-2, influenza or RSV can be similar, it is vital to correctly detect them for treating and managing patients accordingly, especially during the Covid-19 pandemic.

The NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage Assay uses the high-throughput, automated three-step workflow of the NeuMoDx 96 and NeuMoDx 288 molecular systems.

It also has additional system features such as processing capacity, true random access and continuous loading of samples, reagents and consumables while the system is running.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

QIAGEN senior vice-president Jean-Pascal Viola said: “This test will play an important role in differentiating between influenza-like illnesses (ILI) while the burden of COVID-19 continues.

“With its ease of use and true random access, the NeuMoDx will help laboratories maintain throughput for this increased testing volume while continuing routine testing.”

The new 4-plex test adds to the expanding menu of assays on the NeuMoDx platform, which includes tests for blood-borne viruses, sexual and reproductive health, and transplant and immunocompromised disease areas.

Last November, QIAGEN launched the test in the European Union and other markets that accept CE-IVD. With the latest EUA, it will begin marketing the test in the US.